Henri H. Versteeg

VIIa/tissue factor interaction results in a tissue factor cytoplasmic domain-independent activation of protein synthesis, p70, and p90 S6 kinase phosphorylation.

In silico tissue factor analysis: a bit-to-bit comparison.

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.

Tissue factor signal transduction in angiogenesis.

Activation of the canonical beta-catenin pathway by histamine.

Coagulation factors VIIa and Xa inhibit apoptosis and anoikis.

Tissue factor as an evolutionary conserved cytokine receptor: Implications for inflammation and signal transduction.

FVIIa:TF induces cell survival via G12/G13-dependent Jak/STAT activation and BclXL production.

Prostanoids and prostanoid receptors in signal transduction.

Molecular mechanism of violacein-mediated human leukemia cell death.

Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways.

Cutting edge: expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia.

Tetrahydroxyquinone induces apoptosis of leukemia cells through diminished survival signaling.

Emerging insights in tissue factor-dependent signaling events.

Disulfide isomerization switches tissue factor from coagulation to cell signaling.

Evidence for activation of tissue factor by an allosteric disulfide bond.

Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation.

Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity.

Inhibition of tissue factor signaling suppresses tumor growth.

Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals.

Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders.

High factor VIIa levels do not promote tumor metastasis.

Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice.

d-Asb11 is an essential mediator of canonical Delta-Notch signalling.

Tissue factor mutated at the allosteric Cys186-Cys209 disulfide bond is severely impaired in decrypted procoagulant activity.

Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development.

Tissue factor signaling: a multi-faceted function in biological processes.

Tissue factor-dependent chemokine production aggravates experimental colitis.

Thiol pathways in the regulation of tissue factor prothrombotic activity.

Complete abolishment of coagulant activity in monomeric disulfide-deficient tissue factor.

The relationship between tissue factor and cancer progression: insights from bench and bedside.

Evolutionary conservation of the tissue factor disulfide bonds and identification of a possible oxidoreductase binding motif.

Mechanistic view of risk factors for venous thromboembolism.

Nonproteolytic properties of murine alternatively spliced tissue factor: implications for integrin-mediated signaling in murine models.

Tissue factor isoforms in cancer and coagulation: may the best isoform win.

Murine tissue factor coagulant activity is critically dependent on the presence of an intact allosteric disulfide.

Microparticle-associated tissue factor activity in plasma is unaffected by cytolytic chemotherapy treatment in metastatic testicular cancer patients.

New fundamentals in hemostasis.

Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production.

Protease-activated receptor (PAR)2, but not PAR1, is involved in collateral formation and anti-inflammatory monocyte polarization in a mouse hind limb ischemia model.

Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma.

Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrin-dependent manner.

Epidemiology of cancer-associated venous thrombosis.

Hematopoietic microRNA-126 protects against renal ischemia/reperfusion injury by promoting vascular integrity.

Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor?